bx795 profile

BX795: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10077147
CHEMBL ID	577784
CHEBI ID	91439
SCHEMBL ID	3865995
MeSH ID	M0583048

Synonym
HY-10514
n-(3-(4-(3-(thiophene-2-carbonylamino)propylamino)-5-iodopyrimidin-2-ylamino)phenyl)pyrrolidine-1-carboxamide
bx-795, 3
bx-795 ,
bdbm17051
n-(3-{[5-iodo-4-({3-[(thiophen-2-ylcarbonyl)amino]propyl}amino)pyrimidin-2-yl]amino}phenyl)pyrrolidine-1-carboxamide
n-{3-[(5-iodo-4-{[3-(thiophen-2-ylformamido)propyl]amino}pyrimidin-2-yl)amino]phenyl}pyrrolidine-1-carboxamide
cid 10077147
CHEMBL577784
BCP9000467
bx 795
bx795
bx7 ,
HMS3244G15
HMS3244G16
n-[3-[[5-iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide
HMS3244H15
BCPP000310
702675-74-9
BCP0726000131
bx795/bx-795
NCGC00250386-02
NCGC00250386-01
n-(3-(5-iodo-4-(3-(thiophene-2-carboxamido)propylamino)pyrimidin-2-ylamino)phenyl)pyrrolidine-1-carboxamide
CS-0259
S1274
BRD-K47983010-001-01-3
gtpl8006
MLS006011190
smr004702959
AKOS016369934
SCHEMBL3865995
n-[3-[[5-iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide
pyrrolidine-1-carboxylic acid [3-(5-iodo-4-{3-[(thiophene-2-carbonyl)-amino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide
n-(3-((5-iodo-4-((3-(thiophene-2-carboxamido)propyl)amino)pyrimidin-2-yl)amino)phenyl)pyrrolidine-1-carboxamide
AC-32825
DTXSID50435186
J-522980
EX-A262
CHEBI:91439
HMS3651A07
mfcd12546134
SW208681-3
BCP01899
bx-795 hydrochloride
FT-0700352
Q27075609
AS-16196
SB13079
HMS3672K09
CCG-264884
NCGC00250386-12
A866640

Excerpt	Reference	Relevance
"BX795 is a pharmacological inhibitor of the TBK1/IKKɛ complex, which has been reported to augment lentiviral transduction of human NK cells and some cell lines, but it has not been tested with human primary T cells."	( Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795. Denson, C; Fang, Z; Gao, Y; Goswami, A; Harari-Steinfeld, R; Li, L; Marincola, FM; Pelayo, A; Qi, LS; Srivastava, R; Wang, W; Weng, L; Xiong, Q; Yang, Z, 2020)	1.49

Excerpt	Reference	Relevance
"Upon treatment with BX795, PBMCs from IFNpos pSS, SLE, SSc and TLR7-stimulated HCs downregulated the expression of the ISGs MxA, IFI44, IFI44L, IFIT1 and IFIT3."	( TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis. Bodewes, ILA; Dalm, VASH; Groot, N; Huijser, E; Huizinga, R; Kamphuis, S; Tas, L; van Daele, PLA; van Hagen, PM; van Helden-Meeuwsen, CG; Versnel, MA, 2018)	0.8

Excerpt	Reference	Relevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."	( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability. Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022)	0.72
" Our results indicate that orally administered BX795 is very well tolerated, had oral bioavailability of 56%, and reached ocular and genital tissues within the first 15 min of dosing."	( Tolerability, pharmacokinetics, and anti-herpetic activity of orally administered BX795. Date, AA; Shukla, D; Singh, SK; Yadavalli, T, 2023)	1.39

Excerpt	Relevance	Reference
"To evaluate the prophylactic antiviral efficacy, corneal tolerance and toxicity of topically dosed BX795, a non-nucleoside small-molecule inhibitor of herpes simplex virus type-1 (HSV-1)."	( Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye. Aakalu, VK; Ali, M; Ames, J; Iqbal, A; Koganti, R; Shukla, D; Suryawanshi, R; Yadavalli, T, 2020)	1.04
" Past studies have shown that a viral protein translation inhibitor, BX795 is capable of mitigating HSV-2 infection both in vitro and in vivo when dosed therapeutically."	( Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection. Madavaraju, K; Qatanani, F; Shukla, D; Singh, SK; Yadavalli, T, 2021)	1.15
" In this regard, BX795, a small molecule inhibitor has shown significant benefit in the treatment of herpesvirus infections previously when dosed topically."	( Tolerability, pharmacokinetics, and anti-herpetic activity of orally administered BX795. Date, AA; Shukla, D; Singh, SK; Yadavalli, T, 2023)	1.48

Class	Description
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
EWS/FLI fusion protein	Homo sapiens (human)	Potency	8.5117	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	1.2987	0.0000	5.0182	79.2586	AID686947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0060	0.0025	1.4513	9.0000	AID1797580; AID1876013
NUAK family SNF1-like kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0050	0.0013	0.2918	5.0900	AID1845556
Serine/threonine-protein kinase ULK1	Homo sapiens (human)	IC50 (µMol)	0.0870	0.0029	0.1421	0.7850	AID1241330
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)	IC50 (µMol)	0.0295	0.0002	1.0855	5.1286	AID1582162; AID1876015
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)	IC50 (µMol)	0.0650	0.0005	1.8909	9.5000	AID1241332
Serine/threonine-protein kinase ULK2	Homo sapiens (human)	IC50 (µMol)	0.3100	0.0011	0.8222	4.5780	AID1241331
Cyclic GMP-AMP synthase	Homo sapiens (human)	IC50 (µMol)	0.0600	0.0040	3.5160	7.0000	AID1475999
Serine/threonine-protein kinase TBK1	Homo sapiens (human)	IC50 (µMol)	0.0163	0.0022	0.8565	6.2200	AID1575515; AID1582160; AID1582161; AID1876014
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)	EC50 (µMol)	0.0260	0.0010	0.0093	0.0260	AID1799765
Serine/threonine-protein kinase TBK1	Homo sapiens (human)	Kd	0.0728	0.0009	1.7674	49.6010	AID1566451; AID1566453; AID1566454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
intracellular signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
type B pancreatic cell development	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein phosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of protein kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
hyperosmotic response	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
insulin receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of phospholipase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cell migration	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
calcium-mediated signaling	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
actin cytoskeleton organization	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
T cell costimulation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
activation of protein kinase B activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cellular response to insulin stimulus	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
regulation of mast cell degranulation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of angiogenesis	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein autophosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
extrinsic apoptotic signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of sprouting angiogenesis	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
intracellular signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein phosphorylation	NUAK family SNF1-like kinase 1	Homo sapiens (human)
DNA damage response	NUAK family SNF1-like kinase 1	Homo sapiens (human)
cell adhesion	NUAK family SNF1-like kinase 1	Homo sapiens (human)
regulation of cell adhesion	NUAK family SNF1-like kinase 1	Homo sapiens (human)
regulation of myosin-light-chain-phosphatase activity	NUAK family SNF1-like kinase 1	Homo sapiens (human)
regulation of cell population proliferation	NUAK family SNF1-like kinase 1	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	NUAK family SNF1-like kinase 1	Homo sapiens (human)
regulation of cellular senescence	NUAK family SNF1-like kinase 1	Homo sapiens (human)
autophagosome assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein localization	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of cell population proliferation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
macroautophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of macroautophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
neuron projection regeneration	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
neuron projection development	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cellular response to nutrient levels	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
response to starvation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of protein lipidation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
positive regulation of autophagosome assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon extension	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagy of mitochondrion	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
reticulophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
piecemeal microautophagy of the nucleus	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of collateral sprouting	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
immune response	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
gene expression	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of lipid storage	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of type I interferon production	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
response to interferon-beta	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
regulation of protein-containing complex assembly	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
mRNA stabilization	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
defense response to virus	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
type I interferon-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
interleukin-17-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
cellular response to virus	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
peptidyl-serine phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
cell population proliferation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
regulation of glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
protein phosphorylation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
autophagy	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
response to starvation	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
collateral sprouting	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
autophagy of mitochondrion	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
axon extension	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
reticulophagy	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
piecemeal microautophagy of the nucleus	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
negative regulation of collateral sprouting	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
autophagosome assembly	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
activation of innate immune response	Cyclic GMP-AMP synthase	Homo sapiens (human)
pattern recognition receptor signaling pathway	Cyclic GMP-AMP synthase	Homo sapiens (human)
positive regulation of defense response to virus by host	Cyclic GMP-AMP synthase	Homo sapiens (human)
regulation of immunoglobulin production	Cyclic GMP-AMP synthase	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Cyclic GMP-AMP synthase	Homo sapiens (human)
DNA repair	Cyclic GMP-AMP synthase	Homo sapiens (human)
DNA damage response	Cyclic GMP-AMP synthase	Homo sapiens (human)
determination of adult lifespan	Cyclic GMP-AMP synthase	Homo sapiens (human)
cAMP-mediated signaling	Cyclic GMP-AMP synthase	Homo sapiens (human)
cGMP-mediated signaling	Cyclic GMP-AMP synthase	Homo sapiens (human)
positive regulation of type I interferon production	Cyclic GMP-AMP synthase	Homo sapiens (human)
paracrine signaling	Cyclic GMP-AMP synthase	Homo sapiens (human)
innate immune response	Cyclic GMP-AMP synthase	Homo sapiens (human)
regulation of T cell activation	Cyclic GMP-AMP synthase	Homo sapiens (human)
defense response to virus	Cyclic GMP-AMP synthase	Homo sapiens (human)
cGAS/STING signaling pathway	Cyclic GMP-AMP synthase	Homo sapiens (human)
negative regulation of cGAS/STING signaling pathway	Cyclic GMP-AMP synthase	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Cyclic GMP-AMP synthase	Homo sapiens (human)
positive regulation of cellular senescence	Cyclic GMP-AMP synthase	Homo sapiens (human)
cellular response to exogenous dsRNA	Cyclic GMP-AMP synthase	Homo sapiens (human)
activation of innate immune response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
inflammatory response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
response to virus	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
negative regulation of gene expression	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of macroautophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
regulation of type I interferon production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of type I interferon production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of interferon-alpha production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of interferon-beta production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
dendritic cell proliferation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
innate immune response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
defense response to Gram-positive bacterium	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
defense response to virus	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
type I interferon-mediated signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
antiviral innate immune response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cGAS/STING signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
negative regulation of TORC1 signaling	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of TORC1 signaling	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of xenophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
macroautophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein serine/threonine kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein binding	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
ATP binding	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
phospholipase activator activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
phospholipase binding	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein serine kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
p53 binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
ATP binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
metal ion binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein serine kinase activity	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein serine/threonine kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
ATP binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
IkappaB kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein phosphatase binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
ubiquitin protein ligase binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
K48-linked polyubiquitin modification-dependent protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
identical protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
protein binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
ATP binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
DNA binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
chromatin binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
double-stranded DNA binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
protein binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
ATP binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
GTP binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
nucleosome binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
protein homodimerization activity	Cyclic GMP-AMP synthase	Homo sapiens (human)
metal ion binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
2',3'-cyclic GMP-AMP synthase activity	Cyclic GMP-AMP synthase	Homo sapiens (human)
molecular condensate scaffold activity	Cyclic GMP-AMP synthase	Homo sapiens (human)
poly-ADP-D-ribose modification-dependent protein binding	Cyclic GMP-AMP synthase	Homo sapiens (human)
nucleic acid binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein phosphatase binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
phosphoprotein binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytoplasm	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytosol	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
plasma membrane	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
focal adhesion	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
postsynaptic density	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytoplasmic vesicle	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cell projection	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
fibrillar center	NUAK family SNF1-like kinase 1	Homo sapiens (human)
nucleus	NUAK family SNF1-like kinase 1	Homo sapiens (human)
nucleoplasm	NUAK family SNF1-like kinase 1	Homo sapiens (human)
cytoplasm	NUAK family SNF1-like kinase 1	Homo sapiens (human)
microtubule cytoskeleton	NUAK family SNF1-like kinase 1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
mitochondrial outer membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
recycling endosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
omegasome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
Atg1/ULK1 kinase complex	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
nucleus	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
nucleoplasm	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
cytosol	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
PML body	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
mitochondrial membrane	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
serine/threonine protein kinase complex	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
mitochondrial matrix	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
cytoplasmic vesicle membrane	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK2	Homo sapiens (human)
cytoplasm	Cyclic GMP-AMP synthase	Homo sapiens (human)
cytosol	Cyclic GMP-AMP synthase	Homo sapiens (human)
nucleus	Cyclic GMP-AMP synthase	Homo sapiens (human)
nucleoplasm	Cyclic GMP-AMP synthase	Homo sapiens (human)
cytosol	Cyclic GMP-AMP synthase	Homo sapiens (human)
plasma membrane	Cyclic GMP-AMP synthase	Homo sapiens (human)
nuclear body	Cyclic GMP-AMP synthase	Homo sapiens (human)
site of double-strand break	Cyclic GMP-AMP synthase	Homo sapiens (human)
nucleus	Cyclic GMP-AMP synthase	Homo sapiens (human)
site of double-strand break	Cyclic GMP-AMP synthase	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
intracellular membrane-bounded organelle	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
serine/threonine protein kinase complex	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (434)

Assay ID	Title	Year	Journal	Article
AID435362	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435711	Percentage CaMKKbeta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435216	Percentage Aurora B activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514781	Inhibition of PRKX at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514788	Inhibition of ROCK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514059	Inhibition of FLT4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514482	Inhibition of PIM2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514435	Inhibition of MAP3K8 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514050	Inhibition of FGFR1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513817	Inhibition of CAMK2D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514064	Inhibition of GRK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435112	Percentage MAPKAPK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513798	Inhibition of ACVR1B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435878	Percentage PRK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435303	Percentage PHK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514426	Inhibition of KIT at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514454	Inhibition of MET M1250T mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435733	Percentage NEK6 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435630	Percentage RSK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514428	Inhibition of LCK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514456	Inhibition of MST1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435468	Percentage ERK8 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435752	Percentage S6K1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514439	Inhibition of MAP4K5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1582163	Inhibition of IKKepsilon/TBK1 in human MDB-MB-231 cells transduced with lentiviral vector expressing human IRF3 assessed as decrease in poly(I:C)-stimulated IRF3 phosphorylation at S385/386 residues preincubated for 1 hr followed by poly(I:C) addition and	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
AID514471	Inhibition of PAK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514461	Inhibition of NEK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435583	Percentage BRSK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435853	Percentage GSK3-beta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1566453	Binding affinity to phosphorylated TBK1 in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514014	Inhibition of CLK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435861	Percentage JNK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435880	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435584	Percentage CaMK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514486	Inhibition of PLK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514053	Inhibition of FGFR3 K650E mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513794	Inhibition of ABL1 G250E mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514464	Inhibition of NEK7 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435134	Percentage SRPK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514790	Inhibition of ROS1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514423	Inhibition of JAK2 JH1 JH2 domain V617F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514798	Inhibition of SGK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514459	Inhibition of MYLK2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876015	Inhibition of IKK epsilon (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435247	Percentage MNK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435882	Percentage RSK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514490	Inhibition of PRKCB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435366	Percentage NEK2a activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1575515	Competitive inhibition of TBK1 (unknown origin) by immunoprecipitation method	2019	MedChemComm, Dec-01, Volume: 10, Issue:12	Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID435858	Percentage IKKepsilon activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435128	Percentage PKD1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1566452	Selectivity ratio of Kd for IKKepsilon in human HEK293/K562/placenta/HepG2 cell lysate mixture to Kd for TBK1 in human HEK293/K562/placenta/HepG2 cell lysate mixture	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514797	Inhibition of RPS6KB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435460	Percentage CK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435229	Percentage ERK8 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514427	Inhibition of KIT T670I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435616	Percentage NEK2a activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1566468	Binding affinity to AAK1 in human HEK293/K562/placenta/HepG2 cell lysate mixture incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514020	Inhibition of CSNK1D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435302	Percentage PHK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514025	Inhibition of CSNK2A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513805	Inhibition of AMPK A1/B1/G1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435873	Percentage PLK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513793	Inhibition of ABL1 E255K mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514450	Inhibition of MARK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435598	Percentage DYRK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514448	Inhibition of MAPKAPK5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID436063	Percentage Aurora C activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514453	Inhibition of MET at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514033	Inhibition of EGFR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435178	Percentage PKCalpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514472	Inhibition of PAK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514802	Inhibition of SRC N1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435715	Percentage DYRK1A activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514031	Inhibition of DYRK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514814	Inhibition of SYK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514821	Inhibition of PASK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435604	Percentage IKK-beta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513797	Inhibition of ABL2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514035	Inhibition of EGFR L861Q mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514452	Inhibition of MERTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514458	Inhibition of MUSK at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435990	Percentage SGK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435222	Percentage CK1delta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513810	Inhibition of BRAF at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514792	Inhibition of RPS6KA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435127	Percentage PAK4 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435251	Percentage MST2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435589	Percentage CHK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514058	Inhibition of FLT3 D835Y mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513804	Inhibition of ALK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435624	Percentage PRK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514783	Inhibition of PTK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435633	Percentage SGK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435232	Percentage HIPK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514811	Inhibition of STK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514065	Inhibition of GRK7 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514047	Inhibition of ERBB4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514049	Inhibition of FES at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514474	Inhibition of PDGFRalpha at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514799	Inhibition of SGK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435872	Percentage PAK4 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514013	Inhibition of CHEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514044	Inhibition of EPHB3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435609	Percentage MAPKAPK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514818	Inhibition of TYRO3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435825	Percentage PKCalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514436	Inhibition of MAP3K9 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514491	Inhibition of PRKCD at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435849	Percentage DYRK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514076	Inhibition of ITK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1582164	Antiproliferative activity against human SK-MEL-2 cells harboring NRAS/TP53 mutation assessed as reduction in cell viability after 96 hrs by CellTiter-Glo luminescence assay	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
AID435610	Percentage MAPKAPK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435611	Percentage MARK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435811	Percentage PIM1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514026	Inhibition of CSNK2A2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435954	Percentage AMPK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514770	Inhibition of PKCE at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514775	Inhibition of PRKCQ at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514784	Inhibition of RAF1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435465	Percentage ERK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513807	Inhibition of AURKC at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514810	Inhibition of STK25 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514433	Inhibition of MAP2K2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514780	Inhibition of PRKG2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514478	Inhibition of PDK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514018	Inhibition of CSK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435960	Percentage CaMKKalpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514445	Inhibition of MAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513813	Inhibition of BTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514786	Inhibition of RET V804L mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514484	Inhibition of PLK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435109	Percentage JNK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514774	Inhibition of PRKCN at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435111	Percentage Lck activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513816	Inhibition of CAMK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513799	Inhibition of ADRBK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514469	Inhibition of PAK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435498	Percentage RSK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514052	Inhibition of FGFR3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514440	Inhibition of MAPK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514465	Inhibition of NEK9 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876185	Cytotoxicity against HEK cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514060	Inhibition of FRK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514794	Inhibition of RPS6KA4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435346	Percentage EF2K activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514487	Inhibition of PRKACA (PKA) at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514475	Inhibition of PDGFRalpha D842V mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514443	Inhibition of MAPK13 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514808	Inhibition of STK23 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514023	Inhibition of CSNK1G2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435739	Percentage p38-gamma activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514481	Inhibition of PIM1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514070	Inhibition of HIPK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435870	Percentage p38beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514477	Inhibition of PDGFRbeta at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514787	Inhibition of RET Y791F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435236	Percentage JNK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514779	Inhibition of PRKG1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514029	Inhibition of DYRK1A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514444	Inhibition of MAPK14 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513800	Inhibition of ADRBK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514037	Inhibition of EPHA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514796	Inhibition of RPS6KA6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435975	Percentage MKK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514451	Inhibition of MATK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1582162	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and fur	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
AID435305	Percentage PKA activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514467	Inhibition of NTRK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514051	Inhibition of FGFR2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435342	Percentage CK1delta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435467	Percentage ERK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514038	Inhibition of EPHA3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1566454	Binding affinity to TBK1 in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID435132	Percentage Src activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514011	Inhibition of CDK2/cyclin A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435382	Percentage TBK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514062	Inhibition of GRK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435353	Percentage HIPK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514021	Inhibition of CSNK1E at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435617	Percentage NEK6 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513808	Inhibition of BLK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435736	Percentage p38delta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514430	Inhibition of LYN A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1241332	Inhibition of recombinant PDK1 (unknown origin) using PDK1tide substrate incubated for 7 mins	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1.
AID514043	Inhibition of EPHB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1566455	Binding affinity to phosphorylated BMP2K in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID435377	Percentage S6K1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514441	Inhibition of MAPK11 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435839	Percentage AMPK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514819	Inhibition of YES1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1845556	Inhibition of NUAK1 (unknown origin)	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Development and Therapeutic Potential of NUAKs Inhibitors.
AID514466	Inhibition of NTRK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435354	Percentage HIPK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514776	Inhibition of PRKCZ at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514473	Inhibition of PAK7 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514016	Inhibition of CLK3 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1566456	Binding affinity to phosphorylated ST17B in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514772	Inhibition of PRKCH at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435594	Percentage CK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435817	Percentage PKBbeta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435596	Percentage CSK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1876109	Cytotoxicity against human HeLa cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435857	Percentage IKKepsilon activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514820	Inhibition of ZAP70 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514442	Inhibition of MAPK12 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514795	Inhibition of RPS6KA5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513809	Inhibition of BMX at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513801	Inhibition of AKT1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435740	Percentage PKCzeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435758	Percentage TBK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514431	Inhibition of LYN B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435249	Percentage MSK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514777	Inhibition of PRKD1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435457	Percentage CHK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1241331	Inhibition of SUMO-tagged ULK2 (unknown origin) kinase domain expressed in KRX cells using [32P]-gamma-ATP and myelin basic protein substrate incubated for 7 mins	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1.
AID435177	Percentage PKA activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514782	Inhibition of PTK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435301	Percentage PDK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513792	Inhibition of ABL1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514801	Inhibition of SRC at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1582160	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM o	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
AID514807	Inhibition of STK22D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514017	Inhibition of CSF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435981	Percentage p38alpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513803	Inhibition of AKT3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID436035	Percentage CaMKKbeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514809	Inhibition of STK24 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514791	Inhibition of RPS6KA1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876014	Inhibition of TBK1 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514012	Inhibition of CDK5/p35 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435371	Percentage p38delta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1582165	Antiproliferative activity against human ACHN cells harboring CDKN2A mutation assessed as reduction in cell viability after 96 hrs by CellTiter-Glo luminescence assay	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
AID436081	Percentage ERK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514424	Inhibition of JAK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514024	Inhibition of CSNK1G3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435477	Percentage MNK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435237	Percentage JNK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514468	Inhibition of NTRK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514470	Inhibition of PAK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876013	Inhibition of PDK1 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514462	Inhibition of NEK4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514073	Inhibition of INSR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514074	Inhibition of INSRR at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514077	Inhibition of JAK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435466	Percentage ERK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435612	Percentage MNK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514438	Inhibition of MAP4K4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513820	Inhibition of CDC42 binding protein beta at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514041	Inhibition of EPHA8 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435337	Percentage Aurora B activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514817	Inhibition of TEK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435344	Percentage DYRK1A activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513795	Inhibition of ABL1 T315I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514447	Inhibition of MAPKAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435976	Percentage MNK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435845	Percentage CHK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435964	Percentage DYRK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514771	Inhibition of PKCG at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435986	Percentage PLK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435922	Percentage PIM3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514485	Inhibition of PLK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435920	Percentage PIM2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435914	Percentage PAK5 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435435	Percentage CaMK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514036	Inhibition of EPHA1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435634	Percentage Src activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514055	Inhibition of FGR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435735	Percentage NEK7 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514028	Inhibition of DCAMKL2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514816	Inhibition of TBK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514460	Inhibition of NEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514480	Inhibition of PHKG2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513815	Inhibition of CAMK2A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID436065	Percentage BRSK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514805	Inhibition of SRPK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514078	Inhibition of JAK2 JH1 JH2 domain at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435917	Percentage PAK6 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435243	Percentage MARK3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435224	Percentage DYRK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514483	Inhibition of PKN1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435470	Percentage HIPK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514057	Inhibition of FLT3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513818	Inhibition of CAMK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435730	Percentage MAPKAPK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514429	Inhibition of LTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435627	Percentage ROCK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435299	Percentage PAK5 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1566484	Binding affinity to ST17B in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514463	Inhibition of NEK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514773	Inhibition of PRKCI at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514437	Inhibition of MAP4K2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514789	Inhibition of ROCK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514476	Inhibition of PDGFRalpha T674I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513811	Inhibition of BRAF V599E mutant at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514800	Inhibition of SGKL at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514027	Inhibition of DAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514489	Inhibition of PRKCB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1566451	Binding affinity to TBK1 in human HEK293/K562/placenta/HepG2 cell lysate mixture incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514804	Inhibition of SRPK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435372	Percentage p38-gamma activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435815	Percentage PKBalpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435927	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435846	Percentage CSK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514010	Inhibition of CDK1/cyclin B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514068	Inhibition of HCK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876184	Cytotoxicity against human HCE cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514063	Inhibition of GRK5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514054	Inhibition of FGFR4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514778	Inhibition of PRKD2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435239	Percentage JNK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435369	Percentage p38alpha activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435875	Percentage PRAK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435254	Percentage p38beta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1875922	Antiviral activity against HSV-1	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435916	Percentage PAK6 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513812	Inhibition of BRSK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514045	Inhibition of EPHB4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435475	Percentage MKK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514434	Inhibition of MAP2K6 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435961	Percentage CDK2-cyclinA activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514815	Inhibition of TAOK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513814	Inhibition of CAMK1D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514034	Inhibition of EGFR L858R mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514066	Inhibition of GSK3A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514067	Inhibition of GSK3B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435732	Percentage MSK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514015	Inhibition of CLK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514042	Inhibition of EPHB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514457	Inhibition of MST4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514813	Inhibition of STK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435122	Percentage NEK7 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513806	Inhibition of AURKB at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514488	Inhibition of PRKCA at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514432	Inhibition of MAP2K1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514056	Inhibition of FLT1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435538	Percentage PDK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1241333	Inhibition of autophagy in human HeLa cells assessed as induction of LC3-I protein accumulation at 4 uM incubated for 24 hrs by immunoblotting method	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1.
AID514479	Inhibition of PHKG1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514785	Inhibition of RET at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514039	Inhibition of EPHA4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514455	Inhibition of MINK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513819	Inhibition of CDC42 binding protein alpha at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435110	Percentage Lck activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435381	Percentage SRPK1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435548	Percentage CaMKKalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514019	Inhibition of CSNK1A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1241330	Inhibition of SUMO-tagged ULK1 (unknown origin) kinase domain expressed in KRX cells using [32P]-gamma-ATP and myelin basic protein substrate incubated for 7 mins	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1.
AID514030	Inhibition of DYRK1B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1582161	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
AID435217	Percentage Aurora C activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435259	Percentage RSK2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514040	Inhibition of EPHA5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514075	Inhibition of IRAK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435746	Percentage PRAK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1475999	Inhibition of cGAS in human THP1 cells assessed as reduction in salmon sperm dsDNA-induced IFN-beta expression preincubated for 1 hr followed by dsDNA stimulation for 12 hrs by luciferase reporter gene assay	2017	PloS one, , Volume: 12, Issue:9	Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay.
AID435543	Percentage PKCzeta activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435108	Percentage IKK-beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435965	Percentage EF2K activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514446	Inhibition of MAPKAPK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435230	Percentage GSK3-beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435492	Percentage PKD1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435755	Percentage SmMLCK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID513802	Inhibition of AKT2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435974	Percentage MELK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435712	Percentage CHK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514425	Inhibition of KDR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1476000	Cytotoxicity against human THP1 cells assessed as reduction in cell viability by CellTiterGlo assay	2017	PloS one, , Volume: 12, Issue:9	Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay.
AID435919	Percentage PIM1 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1566483	Binding affinity to BMP2K in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
AID514022	Inhibition of CSNK1G1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435813	Percentage PIM3 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514069	Inhibition of HIPK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514032	Inhibition of DYRK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514071	Inhibition of IGF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514449	Inhibition of MARK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID513796	Inhibition of ABL1 Y253F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435187	Percentage CDK2-cyclinA activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514803	Inhibition of SRMS at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514806	Inhibition of STK22B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435379	Percentage SmMLCK activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435921	Percentage PIM2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435437	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514061	Inhibition of FYN at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID435978	Percentage MST2 activity remaining in the presence of 0.01uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514793	Inhibition of RPS6KA3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514812	Inhibition of STK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514072	Inhibition of IKBKB at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID514048	Inhibition of FER at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1876183	Antiviral activity against HSV-2 assessed as reduction in virus titre at 10 uM relative to control	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435359	Percentage JNK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID514046	Inhibition of ERBB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	2009	Nature chemical biology, Jul, Volume: 5, Issue:7	Inhibitor hijacking of Akt activation.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1645871	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1797580	PDK1-mediated AKT2 Activation Assay (cAKT2 33P-SPA) from Article 10.1074/jbc.M501367200: \\Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.\\	2005	The Journal of biological chemistry, May-20, Volume: 280, Issue:20	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
AID1799765	Proliferation Assay from Article 10.1074/jbc.M110.156463: \\Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.\\	2011	The Journal of biological chemistry, Feb-25, Volume: 286, Issue:8	Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
AID1345650	Human checkpoint kinase 1 (CHK1 subfamily)	2005	The Journal of biological chemistry, May-20, Volume: 280, Issue:20	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
AID1345612	Human cyclin dependent kinase 2 (CDK1 subfamily)	2005	The Journal of biological chemistry, May-20, Volume: 280, Issue:20	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
AID1345388	Human 3-phosphoinositide dependent protein kinase 1 (PDK1 family)	2005	The Journal of biological chemistry, May-20, Volume: 280, Issue:20	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
AID1345633	Human glycogen synthase kinase 3 beta (GSK subfamily)	2005	The Journal of biological chemistry, May-20, Volume: 280, Issue:20	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
AID1345506	Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family)	2005	The Journal of biological chemistry, May-20, Volume: 280, Issue:20	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (5.26)	29.6817
2010's	29 (50.88)	24.3611
2020's	25 (43.86)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	54 (94.74%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
b 844-39 [no description available]	2.15	1	diarylmethane
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	3.07	4	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
pd 173074 [no description available]	2.08	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
jtv519 [no description available]	4.24	4
abt 702 [no description available]	2.08	1	bipyridines
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.89	3	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
dan 2163 [no description available]	4.24	4	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.89	3	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.89	3	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.89	3	1-benzofurans; aromatic ketone	uricosuric drug
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.08	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	4.24	4
bisindolylmaleimide iv [no description available]	2.41	1	indoles; maleimides
bufexamac Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.	2.89	3	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cadralazine cadralazine: structure given in first source	4.24	4	organic molecular entity
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.08	1	aromatic ether; nitrile; polyether; tertiary amino compound
carvedilol [no description available]	2.63	2	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
celecoxib [no description available]	2.08	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	2.63	2	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.08	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	2.89	3	diarylmethane
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	2.89	3	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
cyclosporine cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.	2.59	2
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.89	3	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.15	1	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.08	1	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
go 6976 [no description available]	3.04	4	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	2.08	1
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide [no description available]	2.03	1	isoquinolines; sulfonamide
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.46	2	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	4.24	4	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
harmaline Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	oneirogen
harmalol harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure. harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	algal metabolite; EC 1.4.3.4 (monoamine oxidase) inhibitor
homochlorocyclizine homochlorocyclizine: RN given refers to parent cpd	4.24	4	diarylmethane
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.89	3	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ic 261 [no description available]	2.03	1	indoles
ifenprodil ifenprodil: NMDA receptor antagonist	4.24	4	piperidines
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone ZM39923: structure in first source	2.89	3	naphthalenes
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.03	1	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.89	3	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.89	3	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.57	2	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	2.08	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lg 100268 LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source	2.08	1
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.51	2	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	4.24	4	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mephenesin Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.	2.89	3	aromatic ether; glycerol ether
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.08	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.08	1	dihydroxyanthraquinone	analgesic; antineoplastic agent
entinostat [no description available]	2.08	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	2.89	3	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.41	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
olprinone olprinone: RN refers to HCl; structure given in first source	2.08	1	bipyridines
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.08	1	aromatic ether; benzimidazoles; pyridines; sulfoxide
oxibendazole oxibendazole: structure	2.89	3	benzimidazoles; carbamate ester
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine: a 5-HT(1A) ligand; structure in first source	4.24	4
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.89	3	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	4.24	4	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.08	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
1-NA-PP1 [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	3.04	4	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.83	3	indoles
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.08	1	benzothiazoles
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	3.04	4	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
ropinirole [no description available]	2.89	3	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
sb 206553 SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source	2.08	1	pyrroloindole
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.08	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.46	2	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	2.08	1	imidazoles
imatinib [no description available]	2.08	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.07	4	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.08	1
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.08	1	stilbenoid
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.59	2	stilbenoid
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.15	1	aromatic ketone
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.08	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
tyrphostin a9 [no description available]	2.41	1	alkylbenzene	geroprotector
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.	2.89	3	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
zm 336372 N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source	2.03	1	benzamides
zotepine zotepine: structure	4.24	4	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.1	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	4.24	4	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	2.89	3	aromatic ketone
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	2.1	1	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cyclizine Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.	2.21	1	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic
trehalose alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.	2.89	3	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
triclocarban triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.	2.89	3	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	4.87	29	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.03	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
4-tert-octylphenol 4-tert-octylphenol: structure given in first source	2.89	3	alkylbenzene
thiazoles [no description available]	2.17	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ethamivan ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.	2.89	3	methoxybenzenes; phenols
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.08	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
methysergide Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.	2.89	3	ergoline alkaloid
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	4.24	4	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	4.38	5	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
formestane [no description available]	2.08	1	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
hydroxychloroquine sulfate [no description available]	2.08	1
etonitazene etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals	4.24	4
amiloride hydrochloride, anhydrous amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.	2.08	1	hydrochloride	diuretic; sodium channel blocker
clothiapine clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine	4.24	4	dibenzothiazepine
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	4.24	4	aromatic ketone
7-hydroxychlorpromazine 7-hydroxychlorpromazine: RN given refers to parent cpd	2.89	3	phenothiazines
acadesine [no description available]	2.08	1	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
cladribine [no description available]	2.08	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.89	3	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
thenalidine thenalidine: antihistaminic, antipruritic; RN in Chemline for thenalidine calcium: 67250-62-8; structure	4.24	4	dialkylarylamine; tertiary amino compound
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.89	3	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	4.24	4	chlorphenamine
dv 1006 [no description available]	2.89	3
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.08	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
climbazole 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one : A ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3.	2.89	3	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes
10-carboxymethyl-9-acridanone 10-carboxymethyl-9-acridanone: RN given refers to parent cpd	3.31	1	acridines
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	2.08	1	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
triadimenol triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts.	2.89	3	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	2.89	3	isoquinolines
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	4.24	4	aminopyridine
chaetochromin chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A	2.89	3
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.89	3	aromatic ketone
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.08	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	2.08	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
pravadoline [no description available]	2.08	1
zileuton [no description available]	2.08	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
niguldipine [no description available]	2.08	1	diarylmethane
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.08	1	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.	2.08	1	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.08	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.89	3	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.08	1
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.08	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
bendamustine [no description available]	2.08	1	benzimidazoles
aloxistatin aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.	2.21	1	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
caroverine caroverine: structure	2.08	1	quinoxaline derivative
indocate [no description available]	4.24	4
cgs 9343b [no description available]	2.08	1	benzimidazoles
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.08	1	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
2-methoxyestradiol 2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.	2.08	1	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
N(4)-acetylsulfathiazole N(4)-acetylsulfathiazole : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 1,3-thiazol-2-yl group at the nitrogen atom. It is a metabolite of sulfathiazole.	2.89	3	1,3-thiazoles; acetamides; sulfonamide	marine xenobiotic metabolite
cyclizine hydrochloride [no description available]	2.59	2
2,3-trimethylene-4-quinazolone 2,3-trimethylene-4-quinazolone: structure in first source	2.89	3	quinazolines
1,3-dimethyluric acid 1,3-dimethyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trionesubstituted by methyl groups at N-1 and N-3.	2.89	3	oxopurine	metabolite
danofloxacin [no description available]	2.89	3	quinolines
nitrefazole [no description available]	2.89	3	imidazoles
alacepril [no description available]	2.08	1	dipeptide; thioacetate ester	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ubenimex ubenimex: growth inhibitor	2.08	1
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	4.24	4	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
honokiol [no description available]	4.24	4	biphenyls
9-methoxyellipticine 9-methoxyellipticine: RN given refers to parent cpd	2.89	3
3-aminophenoxazone 3-aminophenoxazone: also inhibits sulfatase; structure	2.89	3	phenoxazine
3-deazaneplanocin 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist	2.89	3
tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai	2.89	3	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound
2-chlorodiazepam [no description available]	2.89	3
Polycartine B [no description available]	2.89	3	phenazines
aminoquinuride dihydrochloride [no description available]	2.89	3
4-phenylbutylamine 4-phenylbutylamine: used as a drug partition into lipid bilayers in a cubic liquid-crystalline phase. 4-phenylbutylamine : A phenylalkylamine that is benzene in which one of the hydrogens is substituted by a 4-aminobutyl group.	2.13	1	benzenes; phenylalkylamine; primary amino compound
thioproperazine mesylate [no description available]	4.24	4	phenothiazines
n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.	2.89	3	6-isopentenylaminopurine	cytokinin
4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available]	2.89	3	sulfonamide
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.63	2
sr141716 [no description available]	4.24	4	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
vinpocetine [no description available]	2.08	1
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide [no description available]	2.59	2	aromatic ketone
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.08	1	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
fingolimod fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.	2.89	3	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
triptolide [no description available]	2.08	1	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
tesmilifene [no description available]	4.24	4	diarylmethane
thromboxanes thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.	2.53	2
sr 48692 SR 48692: structure in first source; a neurotensin receptor-1 antagonist	2.08	1	N-acyl-amino acid
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	2.08	1
sr 27897 SR 27897: structure given in first source; a CCK(A) receptor antagonist	2.89	3	indolyl carboxylic acid
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.41	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.57	2	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	2.89	3	leucine derivative
bay x 1005 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;	2.08	1
norketamine norketamine: metabolite of ketamine; RN given refers to cpd without isomeric designation	4.24	4	organochlorine compound
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	3.31	1	monocarboxylic acid; xanthones	antineoplastic agent
indatraline indatraline: RN given for (trans)-isomer; structure in first source	2.63	2	indanes
lestaurtinib [no description available]	2.41	1	indolocarbazole
gyki 53655 GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist	2.08	1
methotrexate [no description available]	2.89	3	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
salvinorin a salvinorin A: from the herb, Salvia divinorum	3.78	2	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
cki 7 N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source. N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I.	2.03	1	isoquinolines; organochlorine compound; primary amino compound; sulfonamide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide 4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol	2.89	3
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis	2.89	3	phenylindole
ml-3000 [no description available]	2.08	1
l 741626 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source	4.24	4	piperidines
cd 437 CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.	2.08	1	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.54	2	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
perifosine [no description available]	2.08	1	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
dx 8951 [no description available]	2.89	3	pyranoindolizinoquinoline
mk 767 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source	2.08	1
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	2.03	1
bazedoxifene acetate [no description available]	2.08	1
canertinib [no description available]	2.57	2	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
birb 796 [no description available]	2.46	2	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
tipifarnib [no description available]	3.07	4	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	3.39	6	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
avasimibe [no description available]	2.89	3	monoterpenoid
sb 203580 [no description available]	2.79	3	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.03	1	indoles; maleimides
enzastaurin [no description available]	2.08	1	indoles; maleimides
erlotinib [no description available]	2.57	2	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
piboserod Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.	2.08	1
l 163191 [no description available]	4.38	5
dizocilpine [no description available]	4.24	4	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
bd 1047 N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity	2.08	1	primary amine
s-benzylcysteine [no description available]	2.89	3	S-aryl-L-cysteine zwitterion
chelidonine chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)	2.89	3	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid
lapatinib [no description available]	4.38	5	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	2.79	3	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	2.08	1	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	aminoquinoline
roxindole [no description available]	2.89	3	indoles	alpha-adrenergic antagonist; serotonergic drug
sr 142806 [no description available]	2.08	1
conidendrin [no description available]	2.89	3
Porfiromycine [no description available]	2.89	3	mitomycin
nsc 95397 [no description available]	2.89	3	1,4-naphthoquinones
4-methyl-2-quinazolinamine 4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source	2.89	3
2-glycineamide-5-chlorophenyl-2-pyrryl ketone [no description available]	2.89	3
elesclomol [no description available]	2.08	1	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer
wortmannin [no description available]	2.03	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
niguldipine hydrochloride [no description available]	2.63	2
2,5-bis(5-hydroxymethyl-2-thienyl)furan [no description available]	2.89	3	thiophenes
nsc 663284 NSC 663284: structure in first source	2.08	1	quinolone
bortezomib [no description available]	2.08	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	4.24	4	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.53	2	cyclohexenones
nsc 23766 [no description available]	2.08	1	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
Destruxin B [no description available]	4.24	4	cyclodepsipeptide
tosylphenylalanyl chloromethyl ketone Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.	2.89	3	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.21	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
pd 166326 PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor	2.41	1
gw 3965 GW 3965: a liver X receptor ligand	2.08	1	diarylmethane
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.03	1
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.46	2	aromatic amide
h 1152 (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.	2.03	1	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1
purvalanol b purvalanol B: protein kinase inhibitor; structure in first source	2.08	1	purvalanol	protein kinase inhibitor
y-700 [no description available]	2.08	1
repsox RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect	2.08	1	pyrazolopyridine
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.03	1	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.51	2	purvalanol
sitafloxacin [no description available]	2.21	1	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide [no description available]	2.08	1	tropane alkaloid
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.89	3
jp-1302 [no description available]	4.24	4
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one [no description available]	4.24	4	benzodiazepine
tenatoprazole Tenatoprazole: structure in first source	4.24	4	imidazopyridine
s 1033 [no description available]	3.28	5	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
5-[(2-fluoroanilino)methyl]-8-quinolinol [no description available]	2.89	3	hydroxyquinoline
benidipine hydrochloride [no description available]	2.59	2
benidipine benidipine: RN refers to (R,R)-(+-)-isomer	3.78	2
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one [no description available]	2.89	3	quinazolines
chlorprothixene (E)-chlorprothixene : A chlorprothixene in which the double bond adopts an (E)-configuration.	4.24	4	chlorprothixene
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.08	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
jrf 12 N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor	4.24	4
rg108 RG108: DNA methyltransferase inhibitor; structure in first source	2.08	1	indolyl carboxylic acid
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester [no description available]	2.89	3	methoxybenzenes; substituted aniline
stf 083010 [no description available]	2.08	1
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.41	1	substituted aniline
3-hydroxypyridine, sodium salt [no description available]	2.89	3
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	3.07	4	naphthalenecarboxamide
5-[(2-bromoanilino)methyl]-8-quinolinol [no description available]	2.89	3	hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide 3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source	2.89	3
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline [no description available]	2.89	3	aromatic amine
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	2.08	1	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide [no description available]	2.89	3	piperidinecarboxamide
secinh3 SecinH3: a small molecule antagonist of cytohesins; structure in first source	2.08	1	triazoles
jk184 JK184: structure in first source	2.08	1
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol [no description available]	2.89	3	hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide [no description available]	2.89	3	acetamides; anilide
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide [no description available]	2.89	3	aromatic amide; thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone [no description available]	2.89	3	dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide [no description available]	2.89	3	aromatic amide
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide [no description available]	2.89	3	aromatic ether
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione [no description available]	2.89	3	maleimides
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	4.35	5	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one [no description available]	2.89	3	dimethoxybenzene
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide [no description available]	2.89	3	quinolines
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine [no description available]	2.89	3	pyrroles
tamoxifen citrate [no description available]	2.08	1	citrate salt	angiogenesis inhibitor; anticoronaviral agent
hc-067047 HC-067047: a TRPA1 antagonist; structure in first source	2.08	1
bi-78d3 [no description available]	3.07	4	aryl sulfide
gsk 3787 [no description available]	2.08	1
sc 514 SC 514: inhibits IkappaB kinase-2; structure in first source	2.03	1	ring assembly; thiophenes
kartogenin kartogenin: promotes chondrocyte differentiation; structure in first source	2.89	3
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.08	1	organonitrogen compound; organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester [no description available]	2.08	1	monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide [no description available]	2.08	1	sulfonamide
LSM-1318 [no description available]	2.08	1	oxa-steroid
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	2.21	1	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.51	2	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
rwj 67657 RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source	2.08	1
6-methyl-2-(phenylethynyl)pyridine 6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.	2.08	1	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.08	1	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
tandutinib [no description available]	2.08	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	4.38	5	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.	2.08	1	hydrochloride	cardiotonic drug
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.28	5	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
7-epi-hydroxystaurosporine [no description available]	2.03	1
zd 6474 CH 331: structure in first source	4.38	5	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide [no description available]	2.63	2	indoles
compound 968 compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.	2.08	1	benzophenanthridine	EC 3.5.1.2 (glutaminase) inhibitor
nih-12848 NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source	2.89	3
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide [no description available]	2.89	3	quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone [no description available]	2.89	3	benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile [no description available]	2.89	3	imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one [no description available]	2.89	3	aromatic ketone
sb-224289 SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.	2.08	1	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester [no description available]	2.89	3	oxopurine
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.08	1	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester [no description available]	2.89	3	organonitrogen compound; organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide [no description available]	2.89	3	quinolines
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.08	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
LSM-1924 [no description available]	2.89	3	organic heterotricyclic compound; organooxygen compound
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine [no description available]	2.08	1	imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine [no description available]	2.08	1	aromatic amine; tertiary amino compound
ferrostatin-1 ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.	2.89	3	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester [no description available]	2.08	1	isoquinolines
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.03	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sch 79797 [no description available]	2.08	1	quinazolines
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine [no description available]	2.89	3	C-nitro compound
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.08	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rabeprazole(1-) [no description available]	2.63	2	organic nitrogen anion
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one [no description available]	2.08	1	monobactam
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.51	2	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.08	1	benzamides
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.08	1	carbazoles; monocarboxylic acid amide; organochlorine compound
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
ncgc00099374 [no description available]	2.89	3
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide [no description available]	2.89	3	benzamides
quercetin [no description available]	2.08	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
luteolin [no description available]	2.89	3	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
cyclosporine [no description available]	2.21	1
kaempferol [no description available]	2.89	3	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.03	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
genistein [no description available]	3.28	5	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.89	3	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
bruceantin [no description available]	2.89	3	triterpenoid
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.03	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.89	3	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	3.31	1	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
daidzein [no description available]	2.89	3	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.51	2	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
neticonazole neticonazole: RN refers to (E)-isomer. neticonazole : An enamine that is ethene which is substituted at positions 1, 1, and 2 by o-pentoxyphenyl, 1H-imidazol-1-yl, and methylthio groups, respectively (the E isomer). An inhibitor of P450-dependent C-14alpha-demethylation of lanosterol (preventing conversion to ergosterol and inhibiting cell wall synthesis in fungi), it is used in Japan (generally as the corresponding hydrochloride salt) as an antifungal drug for the treatment of superficial skin infections.	2.89	3	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.	4.24	4	endocannabinoid; N-acylethanolamine 22:6
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	2.89	3	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.03	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alpha-zearalenol [no description available]	4.24	4	macrolide
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.41	1	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.08	1	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
su 9516 [no description available]	2.89	3
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.89	3	triazolopyrimidines
ter 199 [no description available]	2.08	1
arachidonylcyclopropylamide arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source	2.08	1
sb 277011 SB 277011: structure in first source	4.24	4
ly 320135 LY 320135: cannabinoid receptor antagonist; structure in first source	2.08	1	benzofurans
pd 166285 [no description available]	2.08	1
sb 223412 SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source	2.89	3
sr 59230a [no description available]	2.89	3	tetralins
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	3.14	4	pyrimidines
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	3.07	4	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.46	2
MeJA [no description available]	2.89	3	Jasmonate derivatives
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)- 1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source	2.89	3
pd 161570 PD 161570: structure in first source	2.89	3
bosutinib 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source	2.41	1	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.08	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	2.03	1
su 11248 [no description available]	4.92	5	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	3.28	5	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	3.07	4	sulfonamide
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.11	1	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
virginiamycin factor s1 virginiamycin factor S1: a component of VIRGINIAMYCIN; was EP to VIRGINIAMYCIN 1992-2001. virginiamycin S1 : A cyclodepsipeptide that is N-(3-hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-phenylglycine in which the carboxy group of the 2-phenylglycine moiety has undergone formal intramolecular condensation with the hydroxy group of the N-(3-hydroxypicolinoyl)-L-threonyl to give the corresponding 19-membered ring lactone. It is one of the two major components of the antibacterial drug virginiamycin, produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others.	2.89	3	cyclodepsipeptide; macrolide antibiotic	antibacterial drug; bacterial metabolite
cisplatin [no description available]	2.08	1	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	2.06	1	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680 [no description available]	3.87	3	N-arylpiperazine
fenoterol fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.	2.63	2	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
xib 4035 XIB 4035: a GFRalpha-1 agonist; structure in first source	4.24	4
viroxime [no description available]	2.41	1
gw-5074 [no description available]	2.21	1
d 4476 [no description available]	2.46	2	imidazoles
cyc 116 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source	2.08	1
bay 19-8004 BAY 19-8004: a PDE4 inhibitor; structure in first source	2.08	1
everolimus [no description available]	2.41	1	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
axitinib [no description available]	2.08	1	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
pai 039 tiplaxtinin: inhibitor of plasminogen activator inhibitor-1	2.08	1	indole-3-acetic acids
belotecan belotecan: structure in first source	2.89	3	pyranoindolizinoquinoline
norgestimate [no description available]	2.89	3	ketoxime; steroid ester; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive
b 43 RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).	2.89	3	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
gw2974 GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2	2.08	1	pyridopyrimidine
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine [no description available]	4.24	4
methiazole methiazole: a parasitostatic agent	4.24	4	benzimidazoles; carbamate ester
sb 218795 SB 218795: structure in first source	2.89	3	quinolines
bvt.948 [no description available]	2.89	3
ispinesib [no description available]	2.08	1	benzamides
fk 866 N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source	2.21	1	benzamides; N-acylpiperidine
a 38503 [no description available]	4.24	4
temsirolimus [no description available]	2.08	1	macrolide lactam
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.79	3	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.57	2	substituted aniline
hdac-42 HDAC-42: structure in first source	2.08	1	amidobenzoic acid
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.15	1	ammonium ion derivative
parthenolide [no description available]	2.58	2	sesquiterpene lactone	drug allergen; inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
krn 633 N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source	2.89	3
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone [no description available]	2.08	1	benzamides; N-acylpiperidine
vacuolin-1 vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis	2.41	1
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid [no description available]	2.89	3	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
iniparib [no description available]	2.08	1	carbonyl compound; organohalogen compound
mk 0752 [no description available]	2.08	1
gw 501516 GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.	3.07	4	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
av 412 [no description available]	2.08	1
ag-041r AG-041R: structure in first source	2.08	1
telatinib [no description available]	2.08	1
dolastatin 10 dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.	4.24	4	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.08	1
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.03	1	quinoxaline derivative
spc-839 SPC-839: an inhibitor of activator protein 1; structure in first source	3.07	4
lenvatinib lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.	2.08	1	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
andarine [no description available]	2.08	1	acetamides; anilide
gw843682x [no description available]	2.08	1	(trifluoromethyl)benzenes
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.79	3	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	3.28	5	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
ag 14361 [no description available]	2.08	1	benzimidazoles
sb 265610 [no description available]	2.08	1
valnemulin [no description available]	2.63	2
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	2.89	3	organic heterotricyclic compound; organooxygen compound
fr 148083 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.	2.08	1	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.08	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
osi 930 OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source	3.07	4	aromatic amide
ki 20227 [no description available]	2.08	1
scio-469 SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.	2.08	1	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ticagrelor Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.	2.89	3	aryl sulfide; hydroxyether; organofluorine compound; secondary amino compound; triazolopyrimidines	P2Y12 receptor antagonist; platelet aggregation inhibitor
ssr 69071 SSR 69071: structure in first source	2.08	1	pyridopyrimidine
l 692585 [no description available]	4.24	4	peptide
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	3.21	5	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
sb 210313 [no description available]	2.08	1
gw 4064 [no description available]	2.08	1	stilbenoid
nnc 26-9100 NNC 26-9100: structure in first source	2.89	3	aminopyridine
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine [no description available]	4.24	4
sa 4503 [no description available]	2.08	1
ic 87114 IC 87114: structure in first source	2.08	1	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zibotentan ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation	2.08	1	phenylpyridine
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	3.07	4	aromatic ether
hki 272 [no description available]	2.53	2	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.57	2	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532 [no description available]	2.08	1
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	3.07	4
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.08	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib [no description available]	2.08	1	aromatic ether
tae226 TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source	4.24	4	morpholines
gw0742 GW 610742: structure in first source	3.07	4	monocarboxylic acid
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.46	2	beta-carbolines
bay 41-8543 BAY 41-8543: structure in first source	2.08	1	pyrazolopyridine
u 18666a 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.	2.89	3	hydrochloride	antiviral agent; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; Hedgehog signaling pathway inhibitor; nicotinic antagonist; sterol biosynthesis inhibitor
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.46	2	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
sb 525334 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor	3.07	4	quinoxaline derivative
way-362450 [no description available]	2.08	1	indoles
osu 03012 OSU 03012: a PDK-1 inhibitor; structure in first source	2.41	1	antibiotic antifungal drug; aromatic amide; glycine derivative; organofluorine compound; phenanthrenes; pyrazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
masitinib [no description available]	2.08	1	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.08	1	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.08	1	organic cation
azd 6244 AZD 6244: a MEK inhibitor	4.66	7	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source	3.07	4
a 443654 A 443654: an Akt kinase inhibitor; structure in first source	2.77	3	indoles
apilimod [no description available]	2.41	1
bay 61-3606 [no description available]	2.89	3	pyrimidines
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.	2.08	1	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ar c155858 AR C155858: an MCT1 inhibitor; structure in first source	2.08	1
pik 75 PIK 75: structure in first source	2.41	1
aee 788 AEE 788: structure in first source	2.08	1	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug
saracatinib [no description available]	2.57	2	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
sd-208 [no description available]	3.07	4
vx 702 VX 702: a p38 MAP kinase inhibitor	2.08	1	phenylpyridine
crenolanib [no description available]	2.89	3	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cj 033466 CJ 033466: structure in first source	2.89	3
cc 401 CC 401: an anthrapyrazolone	2.89	3	pyrazoles; ring assembly
sl0101 SL0101: p90 Ribosomal S6 Kinase; structure in first source	2.03	1
volasertib BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source	2.08	1
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	4.38	5	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
arterolane arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.	2.89	3
azd 7762 [no description available]	2.08	1	aromatic amide; thiophenes
cariprazine cariprazine: Structure in first source. cariprazine : An N-alkylpiperazine that is N,N-dimethyl-N'-{trans-4-[2-(piperazin-1-yl)ethyl]cyclohexyl}urea substituted at position 4 on the piperazine ring by a 2,3-dichlorophenyl group. Used (as the hydrochloride salt) for treatment of schizophrenia and bipolar disorder.	4.24	4
krp-203 [no description available]	3.07	4
cyclic diadenosine phosphate cyclic di-AMP : A cyclic purine dinucleotide that is the 3',5'-cyclic dimer of AMP.	3.31	1	adenyl ribonucleotide; cyclic purine dinucleotide	Mycoplasma genitalium metabolite
mk 0354 [no description available]	2.08	1
regorafenib [no description available]	3.28	5	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
at 7867 [no description available]	4.24	4	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester [no description available]	3.07	4	pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.08	1	methoxybenzenes; substituted aniline
ptc 124 [no description available]	4.24	4	oxadiazole; ring assembly
degrasyn degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source	2.63	2
brivanib [no description available]	2.08	1	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
icg 001 [no description available]	2.08	1	peptide
mp470 [no description available]	2.08	1	N-arylpiperazine
nu 7441 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source	2.08	1	dibenzothiophenes
at 7519 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.	2.08	1	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bi 2536 [no description available]	3.28	5
danusertib [no description available]	2.08	1	piperazines
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide [no description available]	2.08	1	benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide [no description available]	2.08	1	benzamides
abt 869 [no description available]	2.08	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
azd 1152 AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.	4.24	4	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.46	2	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066 [no description available]	2.08	1
carfilzomib [no description available]	3.07	4	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
gw9508 GW9508: structure in first source	2.08	1	aromatic amine
jnj 26854165 [no description available]	2.08	1
pf 573228 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source	2.08	1	quinolines
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.08	1
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	3.07	4	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.57	2	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile [no description available]	2.08	1	benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Vx-11e: ERK1-2 inhibitor	2.08	1	aromatic amide; heteroarene
osi 906 [no description available]	2.08	1	cyclobutanes; quinolines
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	2.03	1	pyrazolopyrimidine
ly2109761 [no description available]	2.08	1
chir-265 [no description available]	2.08	1	aromatic ether
motesanib [no description available]	3.07	4	pyridinecarboxamide
az-628 AZ-628: a multikinase inhibitor; structure in first source	2.08	1	benzamides
trametinib [no description available]	2.87	3	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pf-562,271 [no description available]	3.07	4	indoles
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.41	1	pyrrolopyridine
gliocladin c gliocladin C: structure in first source	4.24	4
N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide [no description available]	2.02	1	ureas
sb 706504 [no description available]	2.89	3
veliparib [no description available]	2.08	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648 [no description available]	3.07	4	dibenzothiophenes
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.57	2	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
bgt226 BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.	4.24	4	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
palomid 529 [no description available]	2.08	1
n-desmethyldanofloxacin N-desmethyldanofloxacin: structure given in first source	2.89	3
rabeprazole sodium [no description available]	2.15	1	organic sodium salt
tosedostat [no description available]	2.08	1	carboxylic ester; hydroxamic acid; secondary carboxamide
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide [no description available]	2.41	1	organochlorine compound
mdv 3100 [no description available]	2.08	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
ku 60019 [no description available]	2.08	1
gsk 461364 GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1	3.65	2	(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source	2.08	1
azd 1152-hqpa AZD2811: has antineoplastic activity; structure in first source	2.63	2	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
CDN1163 CDN1163: a SERCA2 activator with antidiabetic activity; structure in first source. CDN1163 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).	2.89	3	aromatic ether; quinolines; secondary carboxamide	SERCA activator
nvp-tae684 [no description available]	3.65	2	piperidines
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source	2.08	1
gsk 269962a [no description available]	3.07	4
a-83-01 A-83-01: an ALK-5 inhibitor; structure in first source	2.08	1
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [no description available]	2.08	1	indoles
vx-770 ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.	2.08	1	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug
buparlisib NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source	2.08	1	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480 [no description available]	2.08	1
azd8330 [no description available]	2.41	1	pyridinecarboxamide
pha 848125 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor	2.89	3
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	3.99	3	sulfonamide
gsk690693 [no description available]	2.08	1	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024 [no description available]	2.08	1	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
ku 0063794 Ku 0063794: an mTOR inhibitor; structure in first source	2.08	1	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source	2.41	1
azd 7545 AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).	2.08	1	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent
nvp-bhg712 [no description available]	2.89	3	benzamides
nutlin-3b [no description available]	2.08	1	Nutlin; piperazinone	anticoronaviral agent
pf 04217903 [no description available]	3.07	4	quinolines
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.08	1	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164 SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source	2.08	1	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one [no description available]	2.89	3	aromatic ketone
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	4.38	5	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408 PHA 408: an IKK-2 antagonist; structure in first source	2.08	1
gsk 1016790a GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.	2.08	1	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist
olaparib [no description available]	2.08	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720 [no description available]	4.38	5
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	2.08	1	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
cx 4945 [no description available]	2.08	1
cudc 101 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source	2.08	1
purfalcamine purfalcamine: a PfCDPK-1 inhibitor; structure in first source	2.89	3
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.08	1	benzazepine
lde225 sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.	2.08	1	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.08	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent
sgx 523 [no description available]	2.08	1	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent
bms 754807 BMS 754807: an IGR-1R kinase inhibitor; structure in first source	2.89	3	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	2.08	1	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	2.08	1	imidazoles
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.57	2	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib [no description available]	3.07	4	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
amg 900 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source	2.08	1
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.08	1	piperazines
bag956 BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies	2.08	1
quizartinib [no description available]	3.07	4	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
PP121 [no description available]	2.89	3	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	2.08	1	carbamate ester
tak 733 [no description available]	2.08	1
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.57	2	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	3.07	4	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
sns 314 SNS 314: an aurora kinase inhibitor; structure in first source	2.08	1	ureas
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.08	1	benzodioxoles
gsk 650394 [no description available]	4.24	4	phenylpyridine
bi d1870 [no description available]	2.03	1
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.	2.57	2	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	3.07	4	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	3.07	4	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide [no description available]	2.08	1	benzamides
incb-018424 [no description available]	2.88	3	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bix 01294 [no description available]	2.08	1	piperidines
pf 3845 PF 3845: inhibits fatty acid amide hydrolase	2.08	1	piperidines
TAK-580 MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.	2.89	3	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor
gsk 2126458 omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.	2.08	1	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one [no description available]	2.89	3	chromones
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.08	1	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
fit-039 FIT-039: CDK9 inhibitor; structure in first source	2.41	1
ldn 193189 LDN 193189: inhibits bone morphogenetic protein signaling	2.08	1	pyrimidines
pf 3758309 PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source	2.89	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
azd2014 vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source	2.41	1
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source	2.63	2	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor
plx4032 [no description available]	2.08	1	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol [no description available]	2.08	1	biphenyls
gsk 1363089 GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source	2.08	1	aromatic ether
kin-193 [no description available]	2.08	1	pyridopyrimidine
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	4.24	4	aryl sulfide; thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	aryl sulfide; thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	aryl sulfide; thienopyrimidine
bay 869766 [no description available]	2.57	2
baricitinib [no description available]	3.14	4	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester WYE-354: an mTOR inhibitor; structure in first source	2.08	1	carbamate ester
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.89	3	quinazolines
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone ML-265: a small molecule activator of PKM2	3.07	4	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide [no description available]	2.89	3	hydroxyquinoline
p505-15 [no description available]	2.89	3
mrt67307 MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source	5.66	8	aromatic amine
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline [no description available]	2.08	1	benzenes; sulfonamide
cp 466722 [no description available]	2.08	1	quinazolines
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source	3.86	2
CAY10626 [no description available]	2.08	1	ureas
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide [no description available]	2.89	3	piperazines
thiopental sodium [no description available]	3.65	2	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
ribociclib ribociclib: inhibits both CDK4 and CDK6	2.89	3
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone [no description available]	2.89	3	aromatic ketone; thienopyrimidine
bay 1000394 roniciclib: an antineoplastic agent that inhibits cyclin-dependent kinases; structure in first source	3.41	1
pha 793887 [no description available]	3.07	4	piperidinecarboxamide
ly2784544 [no description available]	2.41	1	pyridazines
gsk 2334470 GSK 2334470: a PDK1 inhibitor; structure in first source	3.78	2	indazoles
sb 1518 [no description available]	2.41	1
nvp-bsk805 [no description available]	2.08	1
ml228 probe ML228 probe: structure in first source. ML228 : A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.	2.89	3	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator
xmd 8-92 XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.	2.08	1	pyrimidobenzodiazepine	protein kinase inhibitor
pf-03882845 [no description available]	2.89	3
jq1 compound [no description available]	3.07	4	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
jnj38877605 [no description available]	2.08	1	quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide [no description available]	2.08	1	benzothiazoles
dinaciclib [no description available]	2.41	1	pyrazolopyrimidine
pf-04620110 PF-04620110: a DGAT1 inhibitor; structure in first source	2.89	3
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.89	3	benzodiazepine
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	2.41	1	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
glpg0634 [no description available]	2.41	1
birinapant birinapant: a Smac mimetic with antineoplastic activity	2.21	1	dipeptide
torin 1 torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	4.38	5	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.89	3	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
ly2940680 [no description available]	2.08	1
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea [no description available]	3.07	4	ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide [no description available]	2.89	3	(trifluoromethyl)benzenes
ro 4929097 [no description available]	2.08	1	dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound	EC 3.4.23.46 (memapsin 2) inhibitor
ncgc00242364 NCGC00242364: structure in first source	2.89	3	quinazolines
gsk4112 GSK4112: a Rev-erbalpha agonist; structure in first source	2.08	1
delgocitinib delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.	2.41	1	azaspiro compound; N-acylazetidine; nitrile; pyrrolopyrimidine; tertiary amino compound; tertiary carboxamide	anti-inflammatory drug; antipsoriatic; antiseborrheic; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
torin 2 torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.08	1	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor
pf-4708671 [no description available]	2.08	1
gsk1210151a GSK1210151A: inhibitor of the BET family of proteins; structure in first source	2.89	3	imidazoquinoline
hs-173 [no description available]	4.24	4
sr1664 [no description available]	2.89	3	indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide 4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source	2.89	3
incb039110 INCB039110: a JAK1 inhibitor; structure in first source	2.41	1
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide [no description available]	2.83	3	benzamides; N-acylpiperidine
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.59	2	aminoquinoline
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.	2.08	1	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes
belinostat [no description available]	2.08	1	olefinic compound
cudc-907 [no description available]	2.89	3
methacycline Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.	2.21	1
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source	2.08	1	carboxylic acid; pyrroline
methacycline monohydrochloride [no description available]	2.59	2
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid [no description available]	2.89	3	quinolines
a 769662 [no description available]	2.08	1	biphenyls
agi-5198 AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source	2.89	3
on123300 ON123300: a protein kinase inhibitor; structure in first source	3.41	1
cep-32496 agerafenib: inhibitor of RAF family kinases; structure in first source	4.24	4
epz004777 [no description available]	2.89	3	N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid [no description available]	2.89	3	organonitrogen heterocyclic compound
LimKi 3 LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.	2.08	1	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone [no description available]	2.08	1	pyrroles
entecavir [no description available]	2.89	3	benzamides; N-acylpiperidine
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole [no description available]	2.08	1	dipyrrins
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide [no description available]	2.08	1	tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione [no description available]	2.08	1	pyrazines
gsk837149a GSK837149A: structure in first source	2.08	1
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide [no description available]	2.08	1	quinazolines
wnt-c59 2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source	2.08	1
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime [no description available]	2.08	1	indanes
gkt137831 setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative	2.89	3
vx-509 [no description available]	2.89	3
vx-970 berzosertib: an ATR kinase inhibitor	3.14	4	sulfonamide
gs-9973 [no description available]	4.24	4
amg 925 AMG-925 : An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).	2.89	3
gne-618 GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source	4.24	4
g007-lk G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source	2.89	3
volitinib [no description available]	2.89	3
ML355 ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.	4.24	4	benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor
acp-196 acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	2.89	3	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343 GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).	2.89	3	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
agi-6780 AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source	2.89	3
khs101 KHS101: a small molecule accelerates neuronal differentiation in the adult rat	4.24	4
cb-839 [no description available]	2.89	3
gsk-j4 GSK-J4: a JMJD3 inhibitor; structure in first source	2.89	3	organonitrogen heterocyclic compound
pf-06424439 PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source	2.89	3
etp-46464 ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source	2.89	3
wz4003 WZ4003: inhibits both NUAK1 and NUAK2; structure in first source	3.41	1
onc201 TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source	2.89	3
kai407 KAI407: an antimalarial; structure in first source	2.89	3
ldc4297 LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.	2.41	1	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
hth-01-015 [no description available]	3.41	1
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source	2.89	3
enasidenib [no description available]	2.89	3	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
oicr-9429 OICR-9429: antineoplastic; structure in first source	2.89	3
lly-507 LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.	2.89	3
at 9283 [no description available]	3.14	4
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.03	1
chir 258 [no description available]	2.08	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.25	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
osi 027 OSI 027: inhibits both mTORC1 and mTORC2; structure in first source	2.08	1
hypoxanthine [no description available]	2.89	3	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.89	3	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
hli 373 [no description available]	2.08	1
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	2.08	1	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
1-hydroxyphenazine 1-hydroxyphenazine: a virulence factor of Pseudomonas aeruginosa. 1-hydroxyphenazine : A phenazine carrying a hydroxy substituent at the 1-position.	2.89	3	phenazines
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.08	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.08	1	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
xav939 XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.	2.08	1	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor
ag-879 AG-879: structure given in first source	2.41	1
2-carboxyarabinitol 1-phosphate [no description available]	2.08	1
hesperadin [no description available]	2.41	1
ro 24-7429 Ro 24-7429: blocks the action of the HIV tat protein; an analog of Ro 5-3335; Proc Natl Acad Sci U S A 1993 Jul 15;90(14):6395-9	2.89	3	benzodiazepine
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	3.07	4
bis(3',5')-cyclic diguanylic acid [no description available]	3.31	1	cyclic purine dinucleotide; guanyl ribonucleotide	immunomodulator; signalling molecule
cyclic guanosine monophosphate-adenosine monophosphate c-GMP-AMP : A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'-linkages.	3.31	1	adenyl ribonucleotide; cyclic purine dinucleotide; guanyl ribonucleotide
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide [no description available]	2.89	3	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	3.07	4	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
cyclic guanosine monophosphate-adenosine monophosphate 2'-3'-cGAMP : A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'- and 2',5'-linkages respectively.	3.68	2	adenyl ribonucleotide; cyclic purine dinucleotide; guanyl ribonucleotide
sb-590885 N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.	2.08	1	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
rvx 208 apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation	2.89	3
bmn 673 talazoparib: inhibits both PARP1 and PARP2; structure in first source	4.24	4
pf-477736 PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).	2.08	1
fenobam fenobam: in USAN fenobam refers to monohydrate	2.08	1	ureas
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.21	1

Condition	Relationship Strength	Studies
Cancer of Lung [description not available]	2.02	1
B16 Melanoma [description not available]	2.02	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.02	1
Benign Neoplasms [description not available]	2.06	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.06	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.25	5
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Disease Exacerbation [description not available]	3.23	1
2019 Novel Coronavirus Disease [description not available]	2.41	1
Viral Diseases [description not available]	2.41	1
Virus Diseases A general term for diseases caused by viruses.	2.41	1
Herpes Simplex Virus Infection [description not available]	3.35	5
B Virus Infection [description not available]	2.9	2
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	3.35	5
Innate Inflammatory Response [description not available]	2.82	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.82	2
Genital Herpes [description not available]	3.04	3
Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.	3.04	3
Cancer of Pancreas [description not available]	2.21	1
Carcinoma, Ductal, Pancreatic [description not available]	2.21	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.21	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.21	1
Herpes Simplex Keratitis [description not available]	2.25	1
Keratitis, Herpetic A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (KERATITIS, DENDRITIC). (Dictionary of Visual Science, 3d ed)	2.25	1
Cancer of Prostate [description not available]	2.25	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.25	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.31	1
Benign Neoplasms, Brain [description not available]	2.31	1
Astrocytoma, Grade IV [description not available]	2.31	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.31	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.31	1
Intraocular Pressure The pressure of the fluids in the eye.	2.15	1
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.15	1
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	2.15	1
Embolism, Pulmonary [description not available]	2.17	1
Blood Clot [description not available]	2.17	1
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	2.17	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.17	1
Libman-Sacks Disease [description not available]	2.17	1
Sclerosis, Systemic [description not available]	2.17	1
Sicca Syndrome [description not available]	2.17	1
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	2.17	1
Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.	2.17	1
Sjogren's Syndrome Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.	2.17	1
Chronic Primary Open Angle Glaucoma [description not available]	2.08	1
Astrocytosis [description not available]	2.08	1
Glaucoma, Open-Angle Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.	2.08	1
Malignant Melanoma [description not available]	2.1	1
Cancer of Skin [description not available]	2.1	1
Invasiveness, Neoplasm [description not available]	2.1	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.1	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.1	1
Astroviridae Infections Infections with ASTROVIRIDAE, causing gastroenteritis in human infants, calves, lambs, and piglets.	2.11	1
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	2.11	1
Infections, Respirovirus [description not available]	2.11	1
Carcinoma, Epidermoid [description not available]	2.11	1
Cancer of Mouth [description not available]	2.11	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.11	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.11	1
Koch's Disease [description not available]	2.13	1
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.13	1

bx795

Description

Cross-References

Synonyms (53)

Research Excerpts

Overview

Treatment

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (117)

Molecular Functions (32)

Ceullar Components (30)

Bioassays (434)

Research

Studies (57)

Market Indicators

Research Demand Index: 45.22

Study Types

bx795

Description

Cross-References

Synonyms (53)

Research Excerpts

Overview

Treatment

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (117)

Molecular Functions (32)

Ceullar Components (30)

Bioassays (434)

Research

Studies (57)

Market Indicators

Research Demand Index: 45.22

Study Types

Related Drugs (749)

Related Conditions (62)